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Thrombosis is the most important underlying mechanism of coronary artery disease and embolic stroke.
Hence, antithrombotic therapy is widely used in these scenarios. However, not all patients achieve the
same degree of benefit from antithrombotic agents, and a considerable number of treated patients will con-
tinue to experience a new thrombotic event. Such lack of clinical benefit may be related to a wide variabil-
ity of responses to antithrombotic treatment among individuals (i.e., interindividual heterogeneity). Several
factors have been identified in this interindividual heterogeneity in response to antithrombotic treatment.
Pharmacogenetics has emerged as a field that identifies specific gene variants able to explain the variabil-
ity in patient response to a given drug. Polymorphisms affecting the disposition, metabolism, transporters,
or targets of a drug all can be implicated in the modification of an individual’s antithrombotic drug re-
sponse and therefore the safety and efficacy of the aforementioned drug. The present paper reviews the
modulating role of different polymorphisms on individuals’ responses to antithrombotic drugs commonly
used in clinical practice. (J Am Coll Cardiol 2009;54:1041–57) © 2009 by the American College of
Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.04.084b
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ihere is increasing interest in the role of genetic polymor-
hisms in the pathophysiology of cardiovascular disease (1).
ardiovascular disease is complex and multifactorial; there-
ore, multiple genes, including many that are as-yet uniden-
ified, are likely to be involved in thrombotic risk (2). The
ell-demonstrated relevance of common polymorphisms in
eep venous thrombosis encouraged the search for polymor-
hisms involved in arterial thrombosis (3). However, the
nfluence of only 1 polymorphism of a candidate gene is
ikely to be weak in itself, and certainly much weaker than
hat of clinical risk factors such as age or classic cardiovas-
ular risk factors (4). The authors of several large-scale
tudies (4–6) have demonstrated only a minor role of many
ifferent polymorphisms in development and prognosis of
yocardial infarction (MI). It is possible that complex
olymorphism profiles could play a stronger role in throm-
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009, accepted April 14, 2009.oembolic disorders. Although some preliminary studies are
upportive of the latter hypothesis, this effect has yet to be
alidated (7,8). In contrast, a single polymorphism could be
elevant in other aspects of the cardiovascular disease, such
s pharmacogenetics.
Pharmacogenetics has emerged as a field that tries to
dentify specific gene variants that are able to explain the
ariability in patient response to a given drug. This variabil-
ty may explain the efficacy of a specific drug in a given
atient as well as its adverse side effects (9). Polymorphisms
ffecting genes that encode disposition, metabolism, trans-
orters, or targets of the drug can all potentially modify an
ndividual’s response to one therapy and thus explain its
fficacy and safety profiles (10). Because such interindividual
eterogeneity in antithrombotic drug response is less com-
lex than the risk of developing cardiovascular diseases, the
ole of a single functional polymorphism affecting any step
odulating the pharmacokinetics or pharmacodynamics of
drug could potentially be more relevant.
Thrombosis is the most important underlying mechanism
f coronary artery disease and embolic stroke. Hence,
umerous agents with antithrombotic properties, including
latelet inhibitors, antithrombins, oral anticoagulants, and
brinolytics, are commonly used in the treatment of cardio-
ascular disease (11–13). Clinical outcomes associated with
ntithrombotic drug usage are not homogeneous, and an
mportant proportion of treated patients will continue to
xperience a new thrombotic event. Several factors (age,
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bolic disorders such as diabetes
mellitus, and lifestyle variables
such as smoking) have been
identified as being involved in
this interindividual heterogene-
ity. However, these factors can-
not fully explain the variable in-
terindividual response profiles,
suggesting that factors intrinsic
to the patient, such as his or her
genetic makeup, may be in-
volved. This paper reviews the
influence of genetic polymor-
phisms on antithrombotic drug
efficacy.
Search Strategy
and Selection Criteria
Published data for this review
were identified by searches in
MEDLINE and reference lists
from relevant articles. Searches
were concentrated on the follow-
ing key words: pharmacogenetic,
pharmacogenomic, antiplatelet
agents, aspirin, clopidogrel, ticlo-
pidine, GP IIb/IIIa inhibitors,
heparin, oral anticoagulants, di-
coumarins, warfarin, fibrinolytic
rugs, genetic, genes, and polymorphism. Representative stud-
es of various reviews about pharmacogenomics, pharmacoge-
etics, and antithrombotic drugs also were included.
harmacogenetics: A Brief Overview
harmacogenetics is the study of how genetic differences
nfluence the variability in patients’ responses to drugs (14).
ost genetic changes involved in pharmacogenetics are
ommon polymorphisms. Certainly, genetic polymorphism
ould also explain the individual risk of developing an
dverse drug reaction or drug inefficacy (9,15).
Candidate genes encode proteins involved in different
athways of a given treatment (16). Therefore, polymor-
hisms can influence drug metabolism by modifying the
unction of drug-metabolizing enzymes (17). In this case,
andidate polymorphisms shall determine the extent of the
etabolism and, as a consequence, the same administered
ose may reach therapeutic levels in some individuals but
ot in others. In the latter case, this may either be
esponsible for supratherapeutic levels of a given drug (thus
xceeding safety margins and increasing the risk of adverse
ffects or toxicity) or infratherapeutic levels (thus patients
ontinue to be exposed to the risks related to the disease
Abbreviations
and Acronyms
ACS  acute coronary
syndrome
ADP  adenosine
diphosphate
COX  cyclooxygenase
CYP  cytochrome P450
FXIII  factor XIII
GP  glycoprotein
HIT  heparin-induced
thrombocytopenia
HR  hazard ratio
INR  international
normalized ratio
LMWH  low molecular
weight heparin
MDR  multidrug
resistance-associated
protein
MI  myocardial infarction
PCI  percutaneous
coronary intervention
VKA  vitamin K
antagonist
VKOR  vitamin K epoxide
reductase
VKORC1  vitamin K
epoxide reductase subunit 1rocess for which a given drug was prescribed). However, polymorphisms also could modify the pharmacokinetics of a
iven drug by affecting its binding capacity to target proteins
s carriers or receptors (18).
Absorption, distribution, excretion, and targeting to the
ite of action also can be influenced, thus modulating the
ltimate pharmacological response to the drug (19). Finally,
olymorphisms that affect the level or function of the target
f the treatment might also influence the effectiveness of
uch therapy. The study of pharmacogenetics encompasses
he search for answers to the hereditary basis for interindi-
idual differences in drug response with the ultimate goal of
ersonalized therapy selection to reduce the incidence of
dverse drugs reactions and improve treatment efficacy
10,20).
ntiplatelet Agents
he pivotal role of the platelets in the pathogenesis of
therothrombosis emphasizes the importance of early and
ustained antiplatelet therapy. Unfortunately, there are limita-
ions to currently approved antiplatelet agents, and a consid-
rable number of treated patients will experience a new
hrombotic event despite being on recommended treatment
egimens, giving rise to the concept of antiplatelet drug
esistance (21). The definition of antiplatelet drug resistance is
ontroversial; thus, the reported prevalence varies widely, de-
ending on laboratory methods used and/or the population
tudied (22). Several clinical (age, other underlying comorbidi-
ies such as diabetes, lifestyle variables such as smoking, and
mportantly compliance) and cellular (increased platelet turn-
ver, up-regulation of platelet-signaling pathways, drug–drug
nteractions) factors have been involved in this interindividual
esponse heterogeneity. Genetic factors also have been
mplicated as having an important role in patient re-
ponse to antiplatelet drugs (23,24). Importantly, the
ajority of candidate genes in antiplatelet drug resistance
re also implicated in the pre-existent variability in
latelet function (25). Although it has been proposed
hat antiplatelet resistance confers a worse prognosis,
erhaps it may indicate pre-existing greater risk (26).
The most relevant proteins involved in platelet function
nd platelet hyper-reactivity are those expressed on the
latelet surface. These proteins play a key role in the steps
f platelet adhesion, activation, and aggregation. The glyco-
rotein (GP) IIb/IIIa receptor is among the most important
latelet complexes, as demonstrated by the severe bleeding
ssociated with deficiency of these proteins (27). The
latelet GP IIb/IIIa receptor plays a pivotal role in platelet
ctivation and aggregation by binding fibrinogen and von
illebrand factor. Many antiplatelet therapies have this
omplex directly or indirectly as their main target. The GP
Ib/IIIa complex is highly polymorphic. The most studied
olymorphism affecting this complex is the PlA polymor-
hism of the GP IIIa subunit, which is responsible for the
ro33Leu amino acid change. It has been suggested that this
olymorphism modulates platelet function and, in particu-
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September 15, 2009:1041–57 Pharmacogenetics and Antithrombotic Therapyar, the PlA2 allele is associated with increased platelet
eactivity (28).
A second complex in the platelet surface that plays a key
ole in platelet adhesion is the high-affinity receptor for
ollagen, the GP Ia/IIa complex. Some polymorphisms have
een identified that affect the structure and density of this
omplex on the platelet surface. The most relevant is
807T (Phe 224), which, albeit being a silent polymor-
hism affecting the Ia subunit, is associated with varia-
ions in expression of the whole receptor on the platelet
urface (29). Thus, the 807T allele, which is associated
harmacogenetic Studies on Antiplatelet AgentsTable 1 Pharmacogenetic Studies on Antiplatelet Agents
Polymorphism Ref. #s
Aspirin
GP IIIa PlA (Pro33Leu) 28,52–56,5863
GP Ia C807T 29,45,53,6467
COX-1 C50T 45,69,71,72
COX-2 G-765C 45
ADP subtype receptor P2Y12 64,72,74,75
Clopidogrel
Cytochrome P450 CYP3A4 (IVS1012GA) 106,107
Cytochrome P450 CYP2C19 (681GA) 91,9398,100104
MDR1 C3435T and C1236T 102,108,109
GP IIIa PlA (Pro33Leu) 54,110,111
GP Ia C807T 6567,112,113
Protease-activated
receptor-1
14 AT 115
ADP subtype receptor P2Y12 65,87,102,107,11612
Ticlopidine
GP IIIa PlA (Pro33Leu) 60,61
GP IIb/IIIa inhibitors
(Parenteral) GP IIIa PlA (Pro33Leu) 28,61,124129
(Oral) GP IIIa PlA (Pro33Leu) 132DP  adenosine diphosphate; COX  cyclooxygenase; GP  glycoprotein; MDR  multidrug resistanceith up to 10 times more expression of this receptor,
ight affect platelet function and could modify the effect
f antiplatelet drugs. Finally, other antiplatelet therapies
arget platelet receptors such as the adenosine diphos-
hate (ADP) receptor or the generation of compounds
elevant for secondary activation pathways. Table 1 sum-
arizes pharmacogenetic studies on antiplatelet agents.
spirin. Aspirin is the most widespread antithrombotic
gent used in clinical practice because it has been shown to
educe the risk of thrombotic events in patients with various
anifestations of atherosclerotic disease (30–33). The an-
Patients
Studied Functional Effects Clinical Effects
5,000 PlA2 allele would require a
greater dose of aspirin
to reach the same
antiaggregant effect as
wild-type homozygotes
Increased risk of thrombosis and
worse clinical outcomes after
angioplasty and stent implantation
1,170 Associated with collagen
receptor density on the
platelet membrane
surface and greater
platelet reactivity
Conflicting data
563 Associated with higher
levels of TxB2
No clinical data
24 Associated with a higher
reduction of TxB2 levels
after aspirin treatment
No clinical data
980 Associated with reduced
platelet aggregation
after aspirin intake
No clinical data
1,501 Conflicting data No clinical data
8,444 Less reduction of platelet
aggregation with
clopidogrel and lower
plasmatic levels of
clopidogrel’s active
metabolite
Poor clinical outcome after
myocardial infarction and
coronary stent implantation
2,330 Diminished clopidogrel
absorption and active
metabolite formation
Poor clinical outcome after
myocardial infarction
124 Reduced platelet
aggregation with
clopidogrel in the acute
phase of treatment
No clinical data
1,175 T allele shows increased
platelet reactivity,
probably related to
enhanced reactivity to
fibrillar collagens
Increased thrombotic risk in
T-allele carriers
54 Greater platelet reactivity No clinical data
7,143 No consistent functional
changes
Conflicting data
1,318 Conflicting data Conflicting data
1,000 Conflicting data Conflicting data
1,014 Adverse interaction Poor outcomes1-associated protein; TxB2  thromboxane B2.
t
i
l
m
w
s
t
c
t
a
(
r
t
f
a
m
e
A
V
n
t
d
b
a
d
(
C
a
h
N
s
a
1
c
C
i
c
(
d
p
t
a
a
r
h
l
a
p
c
t
v
p
i
t
a
p
i
r
a
g
t
t
t
c
t
o
w
s
e
n
h
a
d
u
t
I
c
o
f
w
m
t
b
i
a
d
o
p
a
e
t
m
s
m
B
p
r
p
p
w
p
1044 Marı´n et al. JACC Vol. 54, No. 12, 2009
Pharmacogenetics and Antithrombotic Therapy September 15, 2009:1041–57iplatelet effects of aspirin are related to its ability to
rreversibly acetylate the cyclooxygenase (COX)-1 enzyme,
eading to the suppression of thromboxane A2 and related
etabolites (34). However, a high percentage of patients
ith symptomatic atherosclerosis can still experience a
erious vascular event despite taking aspirin, which gives rise
o the concept of aspirin resistance (35,36).
Unfortunately, the definition of aspirin resistance remains
ontroversial (37), and the reported range of aspirin resis-
ance varies broadly, from 5% to 40%, depending on the
ssay used for identification and the population studied
38,39). However, strictly speaking the term “resistance”
efers to the inability of an antiplatelet agent to block its
arget. Thus, aspirin resistance should be defined as the
ailure of aspirin to block arachidonic acid-induced platelet
ggregation, inhibiting platelet thromboxane A2 production
ediated by COX-1 (40).
Several laboratory assays are available to test for aspirin
ffects: light transmittance aggregometry, Platelet Function
nalyzer (PFA)-100 (Dade Behring, Deerfield, Illinois),
erifyNow-ASA assay (Accumetrics, San Diego, Califor-
ia), thromboelastography, or the determinations of serum
hromboxane B2 levels or its urinary metabolite 11-
ehydro-thromboxane B2 (22,41). Controversial data have
een recently published regarding the real prevalence of
spirin resistance when it is assessed by methods that
irectly indicate the degree of platelet COX-1 inhibition
42). In fact, studies (43–45) in which the authors used
OX-1–specific assays have shown that the prevalence of
spirin resistance is extremely low (5%).
Importantly, poor compliance of the patient to treatment
as been identified as a primary cause of resistance (42).
evertheless, the authors of several studies (36,46–48) have
hown a relationship between markers of residual platelet
ctivation determined by assays that are not highly COX-
–specific and the risk of new ischemic events or cardiovas-
ular death. Aspirin in fact has been suggested to have
OX-1–independent effects, which may be subject to more
nterindividual variability and may explain the adverse out-
omes among patients with high platelet reactivity (22,44).
Many mechanisms could be related to aspirin resistance
49). Clinical factors, including poor patient compliance,
rug-absorption abnormalities, or drug–drug interactions,
lay a role (50). Importantly, ibuprofen blocks the inhibi-
ion of serum thromboxane B2 formation and platelet
ggregation by aspirin (51). Other conditions and entities
ssociated with enhanced platelet reactivity can modify
esponsiveness (i.e., acute coronary syndrome, congestive
eart failure, dyslipidemia, or exercise) (23). Different cellu-
ar factors have been proposed to influence aspirin efficacy, such
s inadequate suppression of platelet COX-1 due to increased
latelet turnover, overexpression of COX-2 mRNA, erythro-
yte–platelet interaction, catecholamine levels, or the genera-
ion of 8-iso-PGF2 (23).
Genetic background also could play a role in interindi-idual response to antiplatelet drugs, which raises the autative number of candidate polymorphisms that could be
nvolved in the aspirin resistance phenomenon. Several of
hese have been investigated, as summarized in Table 1. The
uthors of different studies (28,52–56) support that the PlA
olymorphism may account for differences in aspirin-
nduced effects. Apparently, carriers of the PlA2 allele would
equire a greater dose of aspirin to experience the same
ntiaggregant effect as do subjects with a PlA1 homozygous
enotype and have an increased risk of cardiovascular
hrombosis (49,52,56–58). It is also interesting to point out
hat some reports found a significant association between
he PlA2 allele and aspirin resistance in complications after
oronary angioplasty (59,60) or after coronary stent implan-
ation (61–63).
The authors of one study (29) investigated the relevance
f the GP Ia C807T polymorphism, which is associated
ith the expression of this collagen receptor on the platelet
urface. However, in most studies (45,53,64,65) performed
ither in patients or healthy control subjects, the authors did
ot find an association with aspirin resistance. However, it
as been observed that the C807T polymorphism and
nother polymorphism of GP Ia, G873A, could be indepen-
ently related with greater platelet reactivity in patients
nder dual antiplatelet therapy (66,67).
Understanding the role of polymorphisms affecting the
arget of aspirin, the COX-1 enzyme, is also of importance.
nterestingly, some polymorphisms of the COX-1 gene
ould modify the activity of the enzyme, having an influence
n aspirin dose requirements (68,69). Hence, our group has
ound that the COX-1 C50T polymorphism is associated
ith thromboxane B2 levels before and after aspirin treat-
ent in healthy subjects (44). Importantly, high levels of
his metabolite have shown to be a good marker of throm-
otic risk in patients treated with aspirin (70). The potential
nfluence of polymorphisms of the COX-2 enzyme on
spirin response was evaluated. A recent Japanese study (71)
id not find any influence of COX-1 or -2 polymorphisms
n platelet responsiveness, but the authors did not find any
atients with the C50T polymorphism. This polymorphism
lso was not found in a Chinese population (72).
These findings underscore the importance of defining
thnicity in pharmacogenetic analyses. Moreover, a func-
ional polymorphism of the COX-2 (G-765C) enzyme also
ight be relevant in aspirin resistance (73). We found a
ignificant association between the COX-2 G-765C poly-
orphism and the efficiency of reduction of thromboxane
2 after aspirin treatment (45). Additional studies should be
erformed to confirm such associations and to evaluate the
ole of these polymorphisms in thromboembolic disease of
atients treated with aspirin.
Other polymorphisms investigated include a C893T
olymorphism in the ADP subtype P2Y1 receptor, but
ithout a clear mechanism involved (74). More recently, the
resence of the P2Y1 893CC genotype appears to confer an
ttenuated antiplatelet effect during aspirin treatment in
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September 15, 2009:1041–57 Pharmacogenetics and Antithrombotic Therapyealthy Chinese volunteers (72). However, these findings
ave not been confirmed in other studies (64,75).
Ultimately, it is important to note that factors extrinsic to
he platelet, such as hemostatic factors, may affect platelet
unction. Therefore, aspirin also may have different degrees of
fficacy according to hemostatic polymorphisms. The
al34Leu polymorphism is a functional genetic change affect-
ng the activation of factor XIII (FXIII), its transglutaminase
ctivity, and the structure of the clot. It has been shown that
nhibition of FXIII activation by aspirin is enhanced in the
eu34 carriers, suggesting that these subjects might benefit
ore than the Leu34-negative subjects from the reduction in
isk for MI with low-dose aspirin (76).
In conclusion, several genetic polymorphisms have been
roposed to influence aspirin response and contribute to
oor prognosis. Of these, the PlA polymorphism appears to
ave the most robust evidence, whereas this is not as sound
ith other COX-1, COX-2, and GP Ia polymorphisms.
hienopyridine derivates. Ticlopidine and clopidogrel are
hienopyridine derivates that irreversibly inhibit the ADP
2Y12 receptor on the platelet surface (77,78). Although
iclopidine has been prescribed in different cardiovascular
isease manifestations, it has been mainly assessed in
ombination with aspirin in patients undergoing percutane-
us coronary intervention (PCI) (79). However, the more
avorable safety profile of clopidogrel (80) has made it the
hienopyridine of choice, mainly as an adjunctive anti-
hrombotic treatment with aspirin to prevent thrombotic
vents after an acute coronary syndrome (ACS) and after
oronary stent implantation, in particular with drug-eluting
tents (81–84). Accumulating data have shown that there is
wide variability in response profiles among clopidogrel-
reated individuals (85). Similarly to aspirin, several meth-
ds have been used to assess clopidogrel-induced antiplate-
et effects (85). Unfortunately, standardized definitions of
ntiplatelet drug responsiveness are lacking. Nevertheless,
here are consistent data that patients who persist with
ncreased platelet reactivity despite clopidogrel, also coined
s suboptimal clopidogrel responders or clopidogrel-
esistant patients, have an increased risk of ischemic events,
ncluding stent thrombosis (86). Recent findings (87,88)
ave shown that a considerable number of patients who
re resistant to clopidogrel also may be resistant to
spirin, which further increases their risk of thrombotic
omplications.
There are no specific pharmacogenetic studies on ticlo-
idine. Most studies were developed under other antiplate-
et agents, and the results are certainly conflicting (60,61), as
hown in Table 1. Interestingly, nonresponders to clopi-
ogrel and ticlopidine are relatively infrequent, suggesting
hat poor response to thienopyridines may be related to a
rug-specific mechanism (89).
Clopidogrel is a pro-drug requiring oxidation by the
epatic cytochrome P450 (CYP) system to generate an
ctive metabolite (85). In particular, approximately 85% of a
lopidogrel dose is hydrolyzed by esterases into an inactive detabolite, whereas the remaining dose is converted into
he active metabolite in a process, which requires 2 sequen-
ial CYP-dependent steps. CYP3A4, CYP3A5, CYP2C9, and
YP1A2 are involved in one step; CYP2B6 and CYP2C19
re involved in both steps (90). Therefore, it was hypothe-
ized (85) that genetic variations of one or more of these
nzymes influences clopidogrel’s antiplatelet effects (Fig. 1).
Several studies have evaluated the influence of polymor-
hisms in the CYP system on clopidogrel response. Of
hese, CYP2C19 was shown to be the most relevant with
onsistent findings in the literature. This finding (90) may
e attributable the fact that this enzyme is involved in both
f the hepatic oxidative steps. This was first shown in a
tudy by Hulot et al. (91), in which the loss-of-function
YP2C19 681GA polymorphism (*2) was associated with
marked decrease in platelet responsiveness to clopidogrel
n young, healthy male volunteers. The explanation for these
ndings is that the gene encoding for CYP2C19, the single
ucleotide polymorphism 681GA (rs4244285) in exon 5,
apped to the long arm of chromosome 10 (10q24.1–
24.3), encodes for a cryptic splice variant resulting in no
nzyme activity in vivo (92).
Fontana et al. (93) confirmed these findings in a healthy
olunteer population but failed to find any influence of this
olymorphism on clopidogrel response when studied in
atients with coronary artery disease (94). However, the
atter was performed in a relatively small cohort of patients,
nd numerous cohort studies (95–100) confirmed the mod-
lating effect of the CYP2C19*2 loss-of-function allele on
lopidogrel response as assessed by various pharmacody-
amic measurements.
The greater prevalence of the CYP2C19*2 loss-of-
unction allele among Asian subjects may explain why the
revalence of suboptimal clopidogrel responders is greater in
apanese patients than in Caucasian ones (96). Geisler et al.
97) showed that prediction of responsiveness after clopi-
ogrel loading dose may substantially be improved by
dding CYP2C19*2 genotype to nongenetic risk factors. In
ddition to pharmacodynamic studies, pharmacokinetic
nalyses (98) have confirmed the role of the CYP2C19 gene
n clopidogrel response and have shown it to be associated
ith variations in the plasmatic levels of clopidogrel’s active
etabolite. The latter study failed to show an impact of this
olymorphism on the plasmatic levels of prasugrel, a third-
eneration thienopyridine with more efficient pharmacoki-
etic, and consequently pharmacodynamic, profiles (98,99).
n a recent study, Trenk et al. (100) showed that patients
arrying at least one CYP2C19*2 allele are more prone to
igh-on clopidogrel platelet reactivity, which was associated
ith poor clinical outcome after coronary stent placement.
More recently, 4 large-scale studies (101–104) have
onfirmed the prognostic implications of the CYP2C19
olymorphism in clopidogrel-treated patients. In a pre-
efined subgroup analysis of the TRITON–TIMI 38 (Trial
t
t
I
s
1
w
d
(
w
5
c
v
1
r
i
c
P
s
C
d
r
j
t
(
s
s
a
s
a
r
r
C
c
d
O
a
a
t
I
o
o
s
o
m
r
(
w
P
w
(
1046 Marı´n et al. JACC Vol. 54, No. 12, 2009
Pharmacogenetics and Antithrombotic Therapy September 15, 2009:1041–57o Assess Improvement in Therapeutic Outcomes by Op-
imizing Platelet Inhibition with Prasugrel–Thrombolysis
n Myocardial Infarction 38) trial (101,105), which showed
ignificantly improved clinical outcomes in patients (n 
3,608) with moderate- to high-risk ACS undergoing PCI
ho were administered prasugrel compared with clopi-
ogrel, a subgroup underwent genetic testing (n  1,477)
101). Carriers of the CYP2C19 reduced function allele,
hich is present in 30% of the study population, had a
3% relative increased risk of the composite end point of
ardiovascular death, nonfatal MI, or nonfatal stroke (12.1%
s. 8.0%; hazard ratio [HR]: 1.53, 95% confidence interval:
.07 to 2.19; p  0.014). These patients also had a 3-fold
isk of stent thrombosis.
These outcomes are attributed to the markedly dimin-
shed pharmacokinetic and pharmacodynamic responses to
lopidogrel associated with CYP2C19 polymorphisms (101).
harmacokinetic and pharmacodynamic responses to pra-
ugrel as well as clinical outcomes were not affected by
YP2C19 polymorphisms associated with reduced clopi-
ogrel metabolism (101). Authors examining a French
egistry of MI (102) showed an increased event rate (ad-
usted HR: 1.98) that was more pronounced in the subgroup
hat underwent PCI (adjusted HR: 3.58). In another study
103), the influence of CYP2C19 polymorphisms was as-
essed in a selected population of young patients who
MDR-1
Platelet membrane receptors
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oronary artery disease before and after a 300-mg loading
ose as well as in the chronic phase of clopidogrel therapy.
f the 5 polymorphisms, only 1 (IVS1012GA) was
ssociated with variable degrees of clopidogrel response, as
ssessed by measures of platelet activation but not aggrega-
ion (106). However, a lack of modulation effects of the
VS1012GA polymorphism on platelet aggregation was
bserved by others (107). The possible influence of CYP3A5
n prognosis has been assessed, without showing any
ignificant influence (102).
The absorption of clopidogrel and thereby active metab-
lite formation have shown to be diminished by P-GP–
ediated efflux and to be influenced by the multidrug
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September 15, 2009:1041–57 Pharmacogenetics and Antithrombotic Therapyoncentrations of clopidogrel varies among individuals and
ay be genetically determined (109).
However, changes in genes encoding platelet glyco-
rotein also have been explored. Indeed, the first study to
valuate the presence of a pharmacogenetic modulation of
lopidogrel response was performed by Angiolillo et al.
110), in which the PlA polymorphism was considered as the
enetic target. Platelet activation before and after a 300-mg
oading dose of clopidogrel was assessed in aspirin-treated
atients undergoing PCI. The study confirmed the modu-
ating effects of this polymorphism on aspirin-induced
ffects and showed that platelet activation was significantly
ttenuated (35% less inhibition) in PlA2 carriers compared
ith the PlA1/A1 genotype (110). At 24 h, GP IIb/IIIa
ctivation persisted significantly greater in PlA1/A2 patients
110). However, the modulating effects of the PlA polymor-
hism on clopidogrel response are limited to the acute phase
f treatment, as no differences were observed in patients on
aintenance therapy (111). The latter finding was also
onfirmed by Cooke et al. (54).
The effect of polymorphisms of other platelet membrane
eceptors on clopidogrel response has also been evaluated.
he role of the GP Ia C807T polymorphism on modulating
latelet function in patients undergoing coronary stenting
eceiving a 300-mg clopidogrel loading dose was also
nalyzed by our group (112). The T allele of the GP Ia gene
as shown to modulate platelet aggregation and clopidogrel
ntiplatelet effects. These findings were confirmed in a
arger cohort of stable patients in the chronic maintenance
hase of clopidogrel therapy (66) as well as those presenting
ith an ACS (67). Overall, these findings suggest an
nhanced reactivity to fibrillar collagens, typically exposed
uring coronary stenting, in T-allele carriers and might
ontribute to the increased thrombotic risk observed in
hese patients (113,114). However, the modulating effects
f the GP Ia C807T polymorphism on clopidogrel response
ere not confirmed by Cuisset et al. (65). Another potential
arget modulating the effects of clopidogrel is the protease-
ctivated receptor-1, the receptor for thrombin on the
latelet surface. Smith et al. (115) showed the intervening
equence-14 AT dimorphism of protease-activated
eceptor-1 to be associated with greater platelet reactivity
efore and after clopidogrel administration.
Because the ADP P2Y12 receptor is the target for the
ctive metabolite of clopidogrel, the authors of several
tudies have investigated the potential role of gene sequence
ariations of this receptor on clopidogrel responsiveness.
ontana et al. (116) identified 5 frequent polymorphisms, of
hich 4 were in total linkage disequilibrium leading to 2
aplotypes (H1 and H2). The H2 haplotype was associated
ith enhanced ADP-induced platelet aggregation in a
ohort of nonmedicated, healthy volunteers. In case-control
tudies in which platelet aggregation was not assessed, this
aplotype was associated with the presence of coronary
rtery disease (117) and peripheral arterial disease (118).
umerous other investigations (87,102,107,119–121) have nherefore evaluated the functional implications of gene
equence variations of the P2Y12 receptor in patients with
oronary artery disease treated with clopidogrel in both the
cute (i.e., after a loading dose) and chronic (i.e., during
aintenance therapy) phases of treatment. However, none
f these studies showed any functional impact of genetic
ariations of the P2Y12 receptor on clopidogrel response or
mpact on clinical outcomes.
In conclusion, there are consistent data that relate clopi-
ogrel variability response to hepatic CYP polymorphisms,
ainly, the CYP2C19 loss-of function polymorphism. Im-
ortantly, in addition to modulation of pharmacodynamic
nd pharmacokinetic profiles, this polymorphism has also
een associated with greater ischemic event rates, including
tent thrombosis. These findings have led many to suggest
enetic testing for this polymorphism as a screening mea-
ure for clopidogrel response. Point-of-care assays are cur-
ently under development to allow rapid genetic testing for
his polymorphism.
he GP IIb/IIIa receptor inhibitors. The relevance of
he GP IIb/IIIa complex in platelet activation and aggre-
ation supports the development of intravenous GP IIb/IIIa
eceptor inhibitors as potent antiplatelet drugs (122). These
rugs have consistently demonstrated their utility in high-
isk patients with ACS, especially those who undergo early
CI (123). The role of polymorphisms, specifically affecting
he target of these agents, has been investigated in this
etting (Table 1). Most studies have evaluated the role of the
lA polymorphism on the antiplatelet effects of GP IIb/IIIa
gents and have obtained controversial results. Some reports
28,124) suggest that GP IIb/IIIa antagonists have lower
latelet-inhibiting effects in carriers of the PlA2 allele. These
ndings are in line with the worse clinical outcomes and
he greatest rates of in-stent restenosis observed in PlA2
arrier patients treated with these agents (62). In con-
rast, other studies (125–128) found no significant effect
f PlA genotype in platelet inhibition or in myocardial
eperfusion (129).
Oral GP IIb/IIIa inhibitors have not demonstrated any
eneficial effect in ACS (130,131). A significant interaction
ith the PlA polymorphism has been suggested to be one of
he causes leading to failure of these drugs (132,133). An
dverse interaction was observed between PlA2 allele and
rbofiban therapy (133). In particular, this finding suggests
hat slight differences in receptor structure, a change of a
roline in place of a leucine at position 33 of GP IIIa, may
nfluence the response to specific GP IIb/IIIa inhibitors, not
nly attenuating any beneficial effect but also contributing
o the increase of deleterious responses.
nticoagulants
nfractionated heparin and low molecular weight heparin
LMWH). Most pharmacogenetic analyses on heparin
134) have been related to heparin-induced thrombocitope-
ia (HIT) and its thromboembolic complications (Table 2).
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Pharmacogenetics and Antithrombotic Therapy September 15, 2009:1041–57ecently, it has been proposed that the PlA2 polymorphism
f the GPIIIa gene may modulate the pro-thrombotic effects
f HIT (135). However, data on this association are not
onsistent (136). There are also controversial data regarding
he association between platelet FcRIIA H131R and
latelet factor 4 polymorphisms with HIT (137–140),
hereas the association of hemostatic polymorphisms with
hromboembolic complications is certainly weak (136).
To the best of our knowledge, there are no published studies
emonstrating a pharmacogenetic effect in LMWHs. How-
ver, it has been suggested that interleukin-1 receptor
ntagonist polymorphisms may be a useful marker to iden-
ify patients that benefit from LMWH in non–ST-segment
levation ACS (141). In particular, carriers of this polymor-
hism showed a better control of von Willebrand factor
ncrease in a small cohort of ACS patients (141).
ral anticoagulants. In 2003, 21.2 million people were
rescribed warfarin for various indications (MI, atrial fibrilla-
ion, stroke, prosthetic heart valve replacement, venous
hrombosis, and major surgery). However, major bleeding
emains a feared adverse effect, especially during the first
eeks of treatment. Vitamin K antagonists (VKAs) in
harmacogenetic Studies That Use Oral Anticoagulant and FibrinolTable 2 Pharmacogenetic Studies That Use Oral Anticoagulant
Polymorphism Ref. #s
Unfractional heparin
GP IIIa PlA (Pro33Leu) 135,136
Fc gamma RIIa-R-H131 137139
Platelet factor 4 137,141
Oral anticoagulants
Cytochrome P450 CYP2C9 150157,159,165
VKOR VKORC1
haplotypes
158165,178
Fibrinolytic drugs
GP IIIa PlA (Pro33Leu) 127,129
MMP-9 C-1562T 191
Plasminogen activator inhibitor-1 4G/5G 192,193
TAFI Thr325Ile 193
Factor XIII Val34Leu 196,197,202204
Angiotensin-converting enzyme I/D 205
Methylenetetrahydrofolate
reductase
C677T 206
NR  international normalized ratio; MMP  matrix metalloproteinase; TAFI  thrombin-activ
bbreviations as in Table 1.eneral are characterized by a marked interpatient and tntrapatient variability, which makes it difficult to determine
he effective dosage. It is well known that the maintenance
ose of VKAs is influenced by different acquired factors,
uch as race, dietary vitamin K intake, comorbid conditions,
cute illness, or comedications (142). Recent advances in
harmacogenetics have been made, and pharmacogenetic-
ased VKA therapy could potentially improve the safety and
ffectiveness of these drugs (143).
The final objective of VKAs consists of decreasing the
mount of reduced vitamin K available for the carboxylation of
lotting factors II, VII, IX, and X (144). This is the reason that
he administration of vitamin K is the antidote for coumarinics
oxicity. Vitamin K-dependent proteins require carboxylation
f key glutamic acid residues for exerting their activity (145).
s a result of the overall scarcity of vitamin K in cells, vitamin
epoxide, generated as a product of gamma-carboxylation,
ust be rapidly recycled to reduced form (KH2) to sustain
urther gamma-carboxylation reactions. The set of sequential
eactions that guarantees vitamin K recycling is known as the
itamin K cycle (Fig. 2) (146). The enzyme that usually
atalyzes the carboxylation reaction is a vitamin K-dependent
amma-glutamil carboxylase, and the enzyme responsible for
rugsFibrinolytic Drugs
Patients
Studied Functional Effects Clinical Effects
205 No functional data Controversial data
517 Controversial data Controversial data
36 No functional data No clinical relevance
8,000 Reduced enzymatic activity Increased response to VKA
and association with
bleeding complications
6,400 Changes at the
transcriptional level
modifies warfarin dose
response
Initial variability in the
INR response
469 No effect No clinical association
61 No effect No clinical association
432 Not assessed No clinical association
139 Not assessed Associated with
recanalization
resistance of middle
cerebral artery after
fibrinolysis
565 Related to differences in
clot resistance
Fibrinolysis less efficient
96 Not assessed DD homozygosis
associated with
recanalization after
fibrinolysis
101 Not assessed 677T homozygosis
independently
associated with
persistently occluded
infarct-related artery
brinolysis inhibitor; VKA  vitamin K antagonist; VKOR  vitamin K epoxide reductase; otherytic Dand
,178he regeneration of vitamin K from vitamin K epoxide is
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September 15, 2009:1041–57 Pharmacogenetics and Antithrombotic Therapyitamin K epoxide reductase (VKOR). The identification of the
KOR gene remained elusive until 2004, when 2 laboratories
sing different approaches (147,148) cloned it. Thus, they
ound that mutations in VKOR occurred in 2 families with
efective vitamin K-dependent clotting factors, in 4 families
ith hereditary warfarin resistance, and in several rat strains
ith resistance to warfarin-like poisons. These studies discov-
red VKOR to be the target of VKAs.
etabolism of VKAs: role of CYP2C9 in interpatient
ariability. The pharmacological effect of either warfarin or
cenocoumarol depends on hepatic metabolism, catalyzed
argely by CYP2C9, a member of the CYP system, which
onverts therapeutic concentrations of these drugs into
nactive metabolites excreted in the urine (149). Then, it
as soon expected that variations in the CYP2C9 gene
ight contribute to interindividual variability in VKA
esponse (Table 2). Semisystematic polymorphism discovery
as conducted in a variety of ethnic populations, and 30
YP2C9 alleles were described. CYP2C9*1 represents the
eference sequence and wild-type allele. The CYP2C9*2 and
YP2C9*3 alleles encode the Arg144Cys and Ile359Leu vari-
nts and are present at allele frequencies of 12% and 8%,
espectively, in Caucasian patients (150). Other polymor-
hisms also identified in Japanese (CYP2C9*4; Arg144/
Figure 2 Vitamin K Cycle
The vitamin K cycle regenerates the reduced form of vitamin K from its epoxide fo
for post-translational gamma-carboxylation of glutamic acid residues of the vitamin
Gamma-carboxylation is catalyzed by a gamma-glutamyl carboxylase and requires t
nists (VKAs) produce their anticoagulant effect, interfering with VKOR activity.hr359) or CYP2C9*5 (Asp360Glu) in African-American catients are less common. The clinical impact of these variants
as been extensively studied.
It is well established that the in vivo elimination of VKAs
s largely influenced by the CYP2C9 genotype. Of note, the
ecreased clearance caused by CYP2C9*2 and *3 alleles also
as a significant clinical impact (151), so that these 2
olymorphisms have been associated with increased respon-
iveness to warfarin. Aithal et al. (152) compared control
atients requiring a typical dose of warfarin with those who
ake 10.5 mg weekly. This second group showed a high
isk of reaching a supratherapeutic international normalized
atio (INR) during the induction phase and a 4-fold risk of
leeding. Also, the presence of *2 and *3 variants in these
atients was 6-fold more frequent. Similarly, the relation-
hip of CYP2C9 genotype with bleeding complications, with
he time to achieve the maintenance dose, and with over-
nticoagulation also has been established (153–155). There-
ore, it has been shown that patients with at least 1 variant
llele had not only an increased risk of a supra-
herapeutic INR, with the consequently increased risk of
leeding, but they also required more time to achieve a
table dose (153). This increased risk of bleeding appears
uring the warfarin initial treatment period but not during
ong-term therapy (156). Similar results have been obtained
ugh the vitamin K epoxide reductase (VKOR). Reduced vitamin K is necessary
endent coagulation factors FII, FVII, FIX, and FX and proteins C, S, and Z.
uced form of vitamin K, molecular oxygen, and carbon dioxide. Vitamin K antago-rm thro
K-dep
he redoncerning other coumarin derivatives (157).
T
(
d
h
n
p
e
g
r
V
p
(
(
C
t
m
p
v
p
w
p
p
w
r
i
a
c
f
r
r
R
f
t
T
i
t
m
p
(
g
m
i
p
w
V
r
t
b
fi
a
r
t
h
p
a
t
o
o
I
t
C
r
p
h
C
t
C
p
p
i
c
d
s
w
a
i
t
4
R
g
p
n
C
a
i
d
g
T
EG
1050 Marı´n et al. JACC Vol. 54, No. 12, 2009
Pharmacogenetics and Antithrombotic Therapy September 15, 2009:1041–57arget of VKAs: vitamin K epoxide reductase subunit 1
VKORC1) genotype and interpatient variability. Un-
erstanding why patients with the same CYP2C9 genotype
ave such a great standard deviation to the mean mainte-
ance dose was critical. This was partly elucidated with the
osterior discovery of the VKOR gene. It is now well
stablished that common polymorphisms in regulatory re-
ions of the VKOR gene correlate strongly with VKA
esponse (Table 2). Rieder et al. (158) resequenced the
KOR gene in almost 200 European-American warfarin
atients and identified 5 haplotypes in the VKOR subunit 1
VKORC1) associated with warfarin dose requirements
Table 2). Among possible variations, a single allelic site,
1173T in intron 1, assigns European-American subjects
o a high- or low-dose group 95% of the time. The
olecular mechanism of this warfarin dose-response ap-
ears to be regulated at the transcriptional level.
Rieder et al. (158) found that VKORC1 mRNA levels
aried according to the haplotype. This highly useful single
olymorphism has been repeatedly shown to be associated
ith optimal coumarin anticoagulant dose in both Euro-
ean and Asian patients (159–162). There are 2 types of
atients exhibiting a clinical phenotype that is compatible
ith partial-to-complete warfarin (or other coumarins)
esistance; the most frequent corresponds to patients carry-
ng the combination of VKORC1 haplotypes for high dose
nd CYP2C9*1*1 genotype, whose incidence has been cal-
ulated as 20% for Caucasian patients (163). Other less-
requent polymorphisms in VKOR, such as R98W, also can
educe VKORC1 activity (164). The second type of warfarin
esistance is caused by single amino acid mutations like
58G, V29L, V45A, and L128R (164). These cases range
rom a very high dose of therapeutic warfarin (40 mg/day)
o complete failure to respond to therapy (147).
oward personalized oral anticoagulation. In a study
ncluding 297 patients with stable anticoagulation geno-
yped for both CYP2C9 and VKORC1 polymorphisms, a
ultivariate regression model including age and height
roduced a model for estimating warfarin dose of R2 55%
165). The performance of commercial platforms for rapid
enotyping of polymorphisms affecting warfarin dose and
odeling stable dose requirements based on clinical, phys-
ologic, environmental, and genetic factors represents a
romising strategic approach to predict individualized stable
arfarin dose requirements (166,167). The initiation of
KA is associated with one of the highest adverse event
ates for any single drug, and physicians often are reluctant
o initiate therapy in elderly patients or patients at risk of
leeding (168). Up to one-half of patients with atrial
brillation and no contraindication to warfarin therapy who
re at high risk of stroke (annual risk4%) are currently not
eceiving anticoagulant therapy because of the risk perceived
o be associated with such therapy by both patients and
ealth care providers (169).
The first month of anticoagulant therapy is especiallyroblematic because the therapeutic dose is empirically
Assessed, and further adjustment is made on the basis of a
rial-and-error strategy. This adjustment leads to the risk of
veranticoagulation with potential bleeding complications
r underanticoagulation with potential thrombotic events.
n a study of approximately 300 patients starting warfarin
herapy, the authors assessed the relationship between
YP2C9 genotypes and VKORC1 haplotypes to the INR
esponses that are used to adjust doses. Conversely to
revious published data, the authors showed that VKORC1
aplotypes modulate the early response to warfarin and not
YP2C9 genotypes. VKORC1 haplotypes predict the time
o reach a first therapeutic INR and the time to an INR4.
YP2C9 genotypes only predict the time to a suprathera-
eutic INR (4) (170).
As previously described, in extensively studied Caucasian
opulations, the CYP2C9 genotype predicts 10% of the
nterpatient variability in warfarin dose. Similarly, in Cau-
asian and Asian populations, the VKORC1 genotype pre-
icts 25% of such variability. The importance of these
trong genetic effects was recognized by recent relabeling of
arfarin by the Food and Drug Administration to increase
wareness in the clinical community (171). However, it is
mportant to note that patient demographics, clinical fac-
ors, and established genetic variants combined only explain
5% to 55% of the total dose variation (Table 3) (171).
ecently published studies in which the authors use a
enome-wide scan strategy for common genetic variants
otentially modulating warfarin response concluded that
one of the other candidate genes (besides VKORC1 and
YP2C9) substantially influence such response (172,173).
The genome-wide analysis of 181 Caucasian individuals
dministered warfarin showed that the most significant
ndependent effect of variation in warfarin maintenance
ose was conferred by polymorphisms in the VKORC1
ene, with lesser associations with the CYP2C9 variants.
he study did not find any significant associations with
stablished Demographic, Clinical, andenetic Factors Influencing Warfarin ResponseTable 3 Established Demog phic, Clinical, andGenetic Factors Influencing Warfarin Response
Variable Effect on Warfarin Dose (%)
Demographic
Age (per decade) 13
BSA (per SD) 15
Caucasian vs. African American 15
Female vs. male 12
Clinical
Target INR (per 0.5 increase) 17
Creatinine clearance (per SD) 10
Amiodarone 24
Drugs that increase INR (per drug) 5
Simvastatin 12
Genetic
CYP2C9*2/*3 genotype 10
VKORC1 C1173T 25dapted from Gage et al. (171).
BSA  body surface area; other abbreviations as in Table 2.
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September 15, 2009:1041–57 Pharmacogenetics and Antithrombotic Therapyther polymorphisms; therefore, it is concluded that the
KORC1 and CYP2C9 genes are the primary genetic
eterminants of stabilized warfarin dose and that common
NPs with large effects on warfarin dose are unlikely to be
iscovered outside of these genes (172). However, these
ata do not discount that other genetic mutations could be
mplied in intermediate phenotypes, which may have a
inor role in the variability in interindividual response
rofiles. Indeed, minor contributions from other genes, such
s gamma-glutamil carboxylase, microsomal epoxide hydro-
ase, apolipoprotein E, MDR1 (174), cytochrome 4F2
175), or calumenin (176), have been described.
The controversy about the relationship between these
ew genetic factors and the pharmacogenetics of VKA
eserves further evaluation. New models will be forthcom-
ng and will continue to evolve with data from large genome
ssociation studies and with the inclusion of acquired or
nvironmental factors not considered to date. Importantly,
t must be kept in mind that important pharmacogenetic
ifferences also exist among VKAs (177). A recent study
hows how clinical and genetic data from 4,043 patients
ere used to create a dose algorithm where genetic data
ere added to clinical variables (178). This pharmacoge-
etic approach produces recommendations that are signifi-
antly closer to the required therapeutic dose than if only
linical data or a fixed-dose were used, although the greatest
enefits were observed in the approximately 50% of the
opulation that required a greater or lesser warfarin dose
han the mean. In any case, randomized, controlled trials are
ecessary to determine whether pharmacogenetic testing is
orthwhile or which patients would better benefit by this
trategy (178). In conclusion, pharmacogenetic studies can
xplain the heterogeneity to VKA response and may be
otentially useful, particularly in patients at the 2 extremes
f dose requirements.
ibrinolytic Drugs
ibrinolytic therapy is used to achieve pharmacological
eperfusion and restoration of flow of an acute coronary
cclusion in patients with an acute ST-segment elevation
I (179), acute ischemic stroke (180), and pulmonary
mbolism (181). Indeed, fibrinolytic therapy leads to better
urvival, recovery of left ventricular function, and remodel-
ng after acute MI (182–184). Thrombolytic therapy within
h of the onset of symptoms of ischemic stroke significantly
educed the number of patients experiencing the combined
nd point of death or dependency (185), and there is good
vidence that thrombolytic therapy accelerates resolution of
ulmonary embolism and results in more rapid hemody-
amic improvement. The evidence that thrombolytic ther-
py improves clinical outcome is less evident (181).
Unfortunately, up to 40% of treated patients do not
chieve optimal tissue perfusion (186), and the potential
enefits are limited by early (thrombotic) reocclusion of the
nfarct-related artery (187). However, a few factors have teen identified to be involved in this interindividual heter-
geneity. They include age, delay between symptom onset
nd fibrinolytic therapy, smoking habits, and infarct size or
ite (188,189). During the last few years, interest has
ncreased regarding initiatives that could improve the effi-
acy of fibrinolytic therapy, including pre-hospital fibrino-
ysis programs, the administration of new drugs (e.g.,
enecteplase), or new pharmacological reperfusion strategies
e.g., half-dose fibrinolytic plus GP IIb/IIIa receptor block-
de or adjunctive clopidogrel therapy) (190).
Only a few studies have analyzed the influence of genetic
actors on the efficacy of fibrinolytic therapy (Table 2). One
tudy (191) analyzed the role of the C-1562T polymorphism
ffecting the promoter region of the matrix metalloproteinase-9
ene in the hemorrhagic transformation of stroke after
brinolytic therapy in 61 patients; the authors found no
ignificant effect. Similarly, negative results were found
hen authors analyzed the relationship between PlA poly-
orphism and myocardial salvage after fibrinolysis
127,129). Again, negative findings were found when au-
hors analyzed plasminogen activator inhibitor-1 4G/5G
olymorphism (192,193).
The FXIII Val34Leu polymorphism is among the most
elevant functional polymorphisms identified in the hemo-
tatic system; thus, it plays a key role in the stability and
tructure of the fibrin clot. Therefore, polymorphisms of
his gene have been evaluated in understanding variations in
ndividual response to fibrinolytic therapy. Activated FXIII
atalyses the formation of covalent gamma-glutamyl-
amma-lysine bonds between fibrin monomers, increasing
he resistance of fibrin to degradation by plasmin (194,195).
he Val34Leu polymorphism affects the function of FXIII
y increasing the rate of FXIII activation by thrombin,
hich results in an increased and faster rate of fibrin
tabilization (196,197). Moreover, interesting reports clearly
emonstrated a different fibrin structure associated with the
XIII Val34Leu genotype (198). However, the thrombotic
ole of this polymorphism is controversial and might be
opulation specific (198–201). The faster activation rate of
he Leu34 variant and the different structure and resistance
f the fibrin-bound clot observed in subjects carrying this
llele encouraged the study of this polymorphism on fi-
rinolytic therapy (197).
In a small and retrospective cohort of patients after a
remature MI, our group (202) observed that Leu34 allele
arriers could show more “resistance” to fibrinolytic therapy.
fterward, we prospectively studied a cohort of patients
rom 2 different European populations undergoing fibrino-
ytic treatment. Evaluation of the efficacy of fibrinolytic
herapy was assessed noninvasively (203). In a multivariate
nalysis, fibrinolysis in patients who carried the Leu34 allele
as significantly less efficient. Re-evaluation at 24 h re-
ealed that the FXIII Val34Leu polymorphism was the only
actor displaying a significant role.
Additionally, we showed that the simultaneous combina-ion of Leu34 allele and nonsmokers significantly increases
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4-h outcome. Accordingly, our study supports that the
ombination of genetic and environmental factors may
xplain the heterogeneity in the efficacy of fibrinolytic
herapy. Overall, these findings may have implications in
linical practice, as demonstrated by a study from our group
valuating the role in the efficacy and side-adverse effects of
hrombolytic therapy in stroke in which patients with the
XIII V/V genotype and low fibrinogen (3.6 g/l) dis-
layed the best clinical outcome (204). In contrast, carriers
f the L34 variant and high fibrinogen levels showed almost
o clinical response. The FXIII V34L polymorphism was
lso associated with mortality (204).
During the past few years, it has been shown that several
olymorphisms can influence the efficacy of fibrinolytic
herapy. Therefore, thrombin-activable fibrinolysis inhibi-
or, TAFI, Thr325Ile (193), and the ACE gene I/D poly-
orphism (205) were associated with recanalization resis-
ance by the end of tissue plasminogen activator infusion in
cute ischemic stroke, assessed by transcranial Doppler,
hereas no association was found between PAI-1 4 G/5 G
olymorphism and recanalization rate (193). Methylenetet-
ahydrofolate reductase C677T polymorphism was indepen-
ently associated with the presence of persistently occluded
nfarct-related artery after thrombolysis (206). Newer stud-
es are warranted to better elucidate the role of genetic
odulation on the efficacy of pharmacological recanaliza-
ion therapy with fibrinolytic agents. In conclusion, prom-
sing results suggest that an underlying genetic background
ould explain the heterogeneity in response to fibrinolytic
rugs.
onclusions
espite being a relatively young field in medicine, pharmaco-
enetics has emerged as a relevant discipline that will help find
he most appropriate treatment for each patient, increasing the
fficacy (improving outcomes) and safety (reducing the side
ffects) of a given drug. Here, we have reviewed the most
mportant polymorphisms that have been associated with
ntithrombotic therapies used in cardiovascular diseases. The
resent review emphasizes the importance of identifying indi-
iduals in whom their potential clinical benefits may be limited
s the result of an inadequate response based on a specific
enetic profile. Titrating antithrombotic drug regimens ac-
ording to antithrombotic function may overcome this phe-
omenon. In clinical practice, all patients are different, and the
dentification of the genetic basis of such heterogeneity will
elp replace general protocols with specific and individualized
reatment regimens. Pharmacogenetics will help the develop-
ent of such personalized medicine.
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